Affinage

EFNB2

Ephrin-B2 · UniProt P52799

Length
333 aa
Mass
36.9 kDa
Annotated
2026-06-09
40 papers in source corpus 24 papers cited in narrative 24 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

EFNB2 (ephrin-B2) is a membrane-bound ligand for EPH-related receptor tyrosine kinases that engages in trans with EPHB4 to drive bi-directional signaling controlling vascular patterning, contractility, and tissue morphogenesis (PMID:8559144, PMID:27530629, PMID:31949258). Binding induces forward (EFNB2-to-EphB4) receptor phosphorylation (PMID:8559144), while reverse signaling through the EFNB2 intracellular tail — with residues 313–331 essential for vascular smooth muscle cell contractility — regulates blood pressure, with EPHB4 identified by crosslinking as the critical forward-signaling receptor in this context (PMID:27530629). The EFNB2/EphB4 axis exerts opposing effects on tumor biology: forward signaling suppresses tumor cell proliferation whereas reverse signaling stimulates endothelial invasion and angiogenesis (PMID:31949258). EFNB2 is positioned downstream of Notch-dependent arterial specification programs, where sox7/Notch/hey2 act upstream of efnb2 and NOTCH4 positively regulates EFNB2 expression in endothelial progenitors (PMID:25834021, PMID:27069008). In development, NKX2-1 directly represses Efnb2 transcription to control dorsoventral cell sorting during tracheoesophageal separation (PMID:35294885), and endothelial EFNB2 supports capillary regeneration and neuromuscular junction recovery after skeletal muscle injury (PMID:39196901). Beyond vasculature, EFNB2 controls T-cell development and IL-6/STAT3-dependent differentiation and chemotaxis (PMID:21976681, PMID:22673212, PMID:25779027), promotes assembly of connexin-30 gap junction plaques in cochlear cells via an Eph receptor-independent reverse-signaling mechanism (PMID:34139316), and acts as a downstream effector in multiple cancer pathways including STAT3/LDLR-mediated cholesterol uptake and mTORC1-ITGA5 signaling (PMID:36376513, PMID:36438491). EFNB2 expression is post-transcriptionally restrained by miR-137 and miR-193a-3p targeting of its 3'-UTR (PMID:27650867, PMID:33585562).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 1995 Medium

    Established EFNB2 as a functional ligand, answering whether the protein actively engages EPH-family receptors rather than merely binding them.

    Evidence cDNA isolation with in vitro receptor binding and phosphorylation assays for ELK and HEK receptors

    PMID:8559144

    Open questions at the time
    • Did not identify EPHB4 as the physiological receptor
    • No cellular or in vivo signaling context defined
    • Reverse signaling not addressed
  2. 2008 Medium

    Linked EFNB2/EPHB4 expression dynamics to arterial versus venous identity in vivo, addressing how positional sorting of vascular cells is specified.

    Evidence Immunohistochemistry time-course in normal and alymphoid mice with lymphocyte transfer rescue

    PMID:18463357

    Open questions at the time
    • Association inferred from expression, not signaling perturbation
    • Direct molecular driver of cell positioning untested
  3. 2011 Medium

    Showed EFNB2 (with EFNB1) is required for IL-6/STAT3 signaling in T cells, revealing a role outside classical Eph-receptor vascular signaling.

    Evidence T cell-specific conditional double knockout mice with STAT3 phosphorylation and differentiation assays

    PMID:21976681

    Open questions at the time
    • Redundancy with EFNB1 obscures EFNB2-specific contribution
    • Biochemical link between EFNB2 and STAT3 not resolved
  4. 2012 Medium

    Defined the limits of EFNB2's non-redundant role in T cell development, distinguishing essential from redundant functions.

    Evidence T cell-specific single EFNB2 knockout mice with flow cytometry and differentiation/activation assays

    PMID:22673212

    Open questions at the time
    • Single-gene phenotype mild due to family redundancy
    • Mechanism of DN3 thymocyte accumulation unknown
  5. 2015 Medium

    Mapped EFNB2 intracellular tail function to T cell chemotaxis and placed efnb2 downstream of sox7/Notch in arterial development.

    Evidence Intracellular tail deletion mutagenesis with chemotaxis/migration assays in mice; zebrafish genetic epistasis with NICD rescue

    PMID:25779027 PMID:25834021

    Open questions at the time
    • Reverse-signaling effectors downstream of the tail unidentified
    • Direct vs indirect Notch-efnb2 link not biochemically resolved
  6. 2016 High

    Identified EPHB4 as the critical forward-signaling receptor and mapped the reverse-signaling domain (aa 313–331) controlling vascular smooth muscle contractility and blood pressure.

    Evidence Smooth muscle-specific conditional KO, crosslinking receptor identification, tail deletion mutagenesis, blood pressure and contractility assays; comparative NOTCH4/NOTCH1 knockdown in EPCs

    PMID:27069008 PMID:27530629

    Open questions at the time
    • Downstream contractile effectors of reverse signaling not defined
    • Sex-specific blood pressure effect mechanism unclear
  7. 2016 Medium

    Established post-transcriptional control of EFNB2 by miR-137 and a 3'-UTR variant, revealing a regulatory layer on EFNB2 abundance.

    Evidence Luciferase reporter assays with wild-type and mutant 3'-UTR constructs, RT-qPCR, western blot

    PMID:27650867

    Open questions at the time
    • Physiological context where miR-137 regulates EFNB2 not defined
    • Phenotypic consequence of the SNP untested in vivo
  8. 2020 Medium

    Demonstrated opposing forward versus reverse signaling outputs in tumor biology and provided a pharmacological tool to bias the axis therapeutically.

    Evidence BIDEN-AP agonist peptide design, in vitro invasion/migration/tube formation, orthotopic tumor model; EFNB2 knockdown in PDAC with p53/p21 cell cycle and EMT readouts

    PMID:31949258 PMID:32036221

    Open questions at the time
    • Direct biochemical link from EFNB2 to p53/p21 not shown
    • Cell-type specificity of forward vs reverse effects incompletely mapped
  9. 2021 Medium

    Revealed an Eph receptor-independent reverse-signaling role for EFNB2 in organizing Cx30 gap junction plaques, broadening the mechanistic repertoire.

    Evidence In situ proximity ligation assay, heterozygous Efnb2 null mice, clathrin internalization and organotypic reverse-signaling activation assays

    PMID:34139316

    Open questions at the time
    • Molecular machinery linking reverse signaling to clathrin internalization unknown
    • Direct Cx30 binding partner of EFNB2 unresolved
  10. 2022 High

    Established direct transcriptional repression of Efnb2 by NKX2-1 and its role in cell-sorting-driven tracheoesophageal separation.

    Evidence ChIP, reporter assays, conditional knockout, lineage tracing, and mosaic NKX2-1 loss-of-function in mice

    PMID:35294885

    Open questions at the time
    • Eph receptor mediating tracheal cell sorting not identified
    • Quantitative threshold of EFNB2 required for boundary formation unknown
  11. 2022 Medium

    Positioned the EFNB2/EPHB4 axis within cancer metabolic and growth signaling, linking it to STAT3/LDLR cholesterol uptake and mTORC1-ITGA5 regulation.

    Evidence In vitro/in vivo CRC liver metastasis models with STAT3 and LDLR assays; Raptor knockdown, transcriptomics, and xenografts in LSCC

    PMID:36376513 PMID:36438491

    Open questions at the time
    • Whether EFNB2 acts via forward or reverse signaling in these contexts not dissected
    • Direct physical interactions upstream/downstream not all validated
  12. 2024 High

    Defined endothelial EFNB2 as required for capillary and neuromuscular junction regeneration after muscle injury, establishing a tissue-repair role.

    Evidence Inducible endothelial-specific conditional KO, BaCl2 injury, isometric force, NMJ morphology and transmission assays

    PMID:39196901

    Open questions at the time
    • Signaling partner mediating regenerative effect unidentified
    • Link between capillary and NMJ defects mechanistically unresolved
  13. 2024 Medium

    Extended EFNB2 signaling to additional contexts: PI3K/AKT-dependent anti-apoptotic effects, RSV host-factor activity, EPHB2-mediated tumor circadian/metabolic reprogramming, and trophoblast EMT regulation.

    Evidence Pathway inhibitor studies in NP cells; gain/loss of function in RSV cell lines; TAM-tumor co-culture and in vivo models; miR-193a-3p luciferase and Transwell assays

    PMID:26277777 PMID:33585562 PMID:38636690 PMID:39298082

    Open questions at the time
    • Directionality (forward/reverse) of signaling not resolved in several contexts
    • Direct EFNB2 molecular interactions in RSV replication unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • How EFNB2 reverse-signaling outputs are mechanistically transduced — the intracellular effectors engaged by the cytoplasmic tail across vascular, cochlear, and developmental contexts — remains undefined.
  • No identified intracellular signaling complex downstream of the EFNB2 tail
  • Receptor-independent reverse-signaling mechanism unresolved
  • Structural basis of context-specific forward vs reverse output unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0048018 receptor ligand activity 3 GO:0060089 molecular transducer activity 3
Localization
GO:0005886 plasma membrane 3
Pathway
R-HSA-1643685 Disease 4 R-HSA-1266738 Developmental Biology 3 R-HSA-162582 Signal Transduction 2
Partners
EPHB2EPHB4

Evidence

Reading pass · 24 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1995 EFNB2 (LERK-5) was identified as a membrane-bound ligand for both ELK and HEK (EPH-related receptor tyrosine kinases) and induces receptor phosphorylation upon binding. cDNA isolation, receptor binding assay, receptor phosphorylation assay in vitro Molecular immunology Medium 8559144
2011 T cell-specific double knockout of Efnb1 and Efnb2 in mice compromised IL-6 signaling, specifically abolishing STAT3 phosphorylation upon IL-6 stimulation, contributing to defects in Th1/Th17 differentiation and antiviral immune response. Conditional knockout mice (loxP-mediated), flow cytometry, in vitro T cell differentiation assays, STAT3 phosphorylation assays The Journal of biological chemistry Medium 21976681
2012 T cell-specific single knockout of EFNB2 alone causes a moderate increase in DN3 thymocyte subpopulation and CD4CD8 double-negative cells, but does not broadly impair T cell activation, proliferation, or Th1/Th2/Th17/Treg differentiation, indicating functional redundancy within the Eph/ephrin family. Conditional knockout mice, flow cytometry, competitive repopulation chimeras, in vitro T cell differentiation and activation assays Molecular immunology Medium 22673212
2015 In T cells, deletion of the intracellular tails of Efnb1 and Efnb2 revealed critical regions controlling T cell chemotaxis toward CXCL12; Efnb1/Efnb2-deficient T cells showed reduced migration to arthritic paws in vivo and impaired chemotaxis in vitro, and provided inferior B cell help for collagen-specific antibody production. Conditional double knockout mice (CIA model), deletion mutagenesis of intracellular tail, in vitro chemotaxis assay, in vivo migration assay, B cell help assay Arthritis & rheumatology (Hoboken, N.J.) Medium 25779027
2016 Smooth muscle cell-specific deletion of EFNB2 in male mice reduced blood pressure. Both forward (EFNB2-to-EPH) and reverse (EPH-to-EFNB2) signaling regulate vascular smooth muscle cell contractility; EPHB4 was identified as the critical receptor for forward signaling by crosslinking studies, and a region from aa 313 to aa 331 in the EFNB2 intracellular tail was essential for reverse signaling regulating VSMC contractility. Smooth muscle cell-specific conditional knockout mice, blood pressure measurement, crosslinking studies, intracellular tail deletion mutagenesis, VSMC contractility assays European journal of human genetics : EJHG High 27530629
2008 In mouse endometrium, uNK cells express EFNB2 early in gestation then transition to EPHB4 expression; spiral arteries shift from EFNB2+/EPHB4- to EFNB2+/EPHB4+, and expression of EFNB2 by uNK cells and trophoblasts is proposed as the mechanism driving their positional association with EFNB2+ arteries and exclusion from EPHB4+ veins. Gain of EPHB4 by midgestation spiral arteries may signal completion of arterial modification. Immunohistochemistry time-course in normal and uNK cell-deficient (alymphoid) mice, lymphocyte transfer rescue experiments Biology of reproduction Medium 18463357
2015 In zebrafish, genetic interaction studies showed that sox7 acts upstream of Notch (with hey2 and efnb2) in arterial specification; loss of sox7, hey2, or efnb2 each produce similar aberrant arteriovenous shunts, and overexpression of Notch intracellular domain rescues the sox7 mutant phenotype, placing sox7 upstream of Notch/hey2/efnb2 in arterial development. Zebrafish mutant generation, in vivo imaging, genetic epistasis (NICD overexpression rescue), in situ hybridization, transgenic reporter lines Development (Cambridge, England) Medium 25834021
2016 NOTCH4 (not NOTCH1) is the specific receptor for the DLL4/NOTCH-EFNB2 cascade in endothelial progenitor cells; NOTCH4 downregulation decreased EFNB2 expression, while NOTCH1 silencing increased EFNB2 expression, demonstrating that NOTCH4 positively regulates EFNB2 expression in this context. siRNA knockdown of NOTCH4 vs NOTCH1 in EPCs, DLL4 stimulation, western blot, functional EPC assays Reproduction (Cambridge, England) Medium 27069008
2020 Trans-interaction between EphB4 and EFNB2 mediates bi-directional signaling: forward EFNB2-to-EphB4 signaling suppresses tumor cell proliferation, while reverse EphB4-to-EFNB2 signaling stimulates invasive and angiogenic properties of endothelial cells; a dual-function agonist peptide (BIDEN-AP) that engages EphB4 suppressed invasion, EMT, and endothelial migration in vitro and reduced orthotopic tumor growth in vivo. Peptide agonist design, in vitro invasion/migration/tube formation assays, in vivo orthotopic tumor model, receptor-mediated endocytosis assay Scientific reports Medium 31949258
2020 Knockdown of EFNB2 in pancreatic ductal adenocarcinoma cells inhibited cell proliferation by upregulating p53/p21-mediated G0/G1 phase cell cycle arrest, and decreased migration and invasion by blocking epithelial-mesenchymal transition. siRNA knockdown in PDAC cell lines, cell cycle analysis, in vitro migration/invasion assays, western blot, in vivo xenograft Biomedicine & pharmacotherapy Medium 32036221
2021 Ephrin-B2 promotes assembly of connexin 30 (Cx30) gap junction plaques between cochlear Deiters' cells; in situ proximity ligation assay showed ephrin-B2 preferentially interacts with Cx30 at the periphery of gap junction plaques. Efnb2 haploinsufficiency causes excessive clathrin-mediated internalization of Cx30 plaques in early postnatal stages. Ectopic activation of ephrin-B2 reverse signaling promotes Cx30 gap junction plaque internalization, suggesting a cell-autonomous, Eph receptor-independent role. In situ proximity ligation assay, heterozygous Efnb2 null mice, clathrin internalization assay, in vitro organotypic assay with ephrin-B2 reverse signaling activation Brain research bulletin Medium 34139316
2022 NKX2-1 directly represses Efnb2 transcription in tracheal cells (demonstrated by chromatin immunoprecipitation and reporter assays); Efnb2 regulates tracheoesophageal separation by controlling dorsoventral allocation of tracheal-fated cells, and ectopic NKX2-1/EPHRIN-B2 boundaries organize ectopic tracheal separation via cell sorting. Conditional knockout mice, chromatin immunoprecipitation (ChIP), reporter assays, lineage tracing, mosaic NKX2-1 loss-of-function Cell reports High 35294885
2022 The EFNB2/EPHB4 axis in colorectal cancer liver metastases promotes LDLR-mediated cholesterol uptake by activating STAT3 phosphorylation, which enhances LDLR transcription; blocking LDLR reversed the tumor-promoting role of the EFNB2/EPHB4 axis. In vitro cell line studies, in vivo mouse model, STAT3 phosphorylation assay, LDLR transcription assay, blocking experiments Oncogene Medium 36376513
2022 ITGA5 (integrin subunit alpha 5), acting as a downstream effector of mTORC1, promotes laryngeal squamous cell carcinoma progression through upregulation of EFNB2, defining an mTORC1-ITGA5-EFNB2 signaling axis. Stable Raptor knockdown, transcriptomic sequencing, western blot, immunofluorescence, xenograft models (CDX and PDX) Theranostics Medium 36438491
2015 EFNB2 expression in MDCK cells (which have low RSV susceptibility) increased RSV replication 10-100 fold; siRNA knockdown of EFNB2 in RSV-susceptible cell lines (HEp-2 and A549) reduced RSV replication, establishing EFNB2 as a positive host factor for RSV replication. cDNA library transfection into MDCK cells, microarray analysis, siRNA knockdown, viral replication assays Virus research Medium 26277777
2024 EFNB2 overexpression in nucleus pulposus cells activated the PI3K/AKT signaling pathway (increased phosphorylation of PI3K, AKT, and mTOR) and inhibited ERK1/2 phosphorylation, thereby reducing apoptosis; these anti-apoptotic effects were partially reversed by PI3K inhibitor LY294002 and ERK activator Ceramide C6 respectively. EFNB2 overexpression and knockdown in NP cells, PI3K inhibitor (LY294002) and ERK activator treatment, western blot for pathway components, apoptosis assays Archives of biochemistry and biophysics Medium 38636690
2024 Endothelial cell-specific conditional knockout of Efnb2 in adult mice delayed capillary regeneration after acute skeletal muscle injury (reduced capillary area at 5 days post-injury) and attenuated recovery of neuromuscular junction structure and function (neuromuscular transmission failure with perturbed pre- and postsynaptic NMJ morphology). Inducible endothelial cell-specific conditional knockout (tamoxifen), BaCl2 muscle injury model, intravascular staining, isometric force measurement, nerve vs. direct stimulation, NMJ morphology analysis The Journal of physiology High 39196901
2016 miR-137 directly targets the 3'-UTR of EFNB2 mRNA and suppresses EFNB2 expression; a genetic variant SNP rs550067317 in the putative seed-pair region of the EFNB2 3'-UTR reverses the repressive effect of miR-137 on EFNB2. Luciferase reporter assays with wild-type and point-mutant 3'-UTR constructs, RT-qPCR, western blot EBioMedicine Medium 27650867
2024 In zebrafish and Caco-2 spheroid cultures, EFNB2 is compartmentalized to the basolateral domain of epithelial cells; EFNB2 is required for epithelial morphogenesis (spheroid organization) acting through its cognate receptor EPHB4, which randomizes mitotic spindle orientation when depleted. EFNB2 is the most abundantly expressed EPHB4 ligand in Caco-2 cells. siRNA/shRNA depletion in Caco-2 spheroids, immunofluorescence localization, mitotic spindle orientation analysis, receptor ligand expression profiling bioRxiv (preprint)preprint Low bio_10.1101_2024.07.15.603563
2021 miR-193a-3p directly targets EFNB2 (confirmed by luciferase activity assay); miR-193a-3p-mediated suppression of EFNB2 promotes EMT (increased N-cadherin, vimentin, MMP2, MMP9; decreased E-cadherin) and enhances trophoblast cell migration and invasion, contributing to placenta accreta spectrum. Luciferase reporter assay, miR-193a-3p overexpression/inhibition, siEFNB2, Transwell migration/invasion assay, western blot for EMT markers Frontiers in molecular biosciences Medium 33585562
2018 Exogenous EFNB2 supplementation stimulated pulmonary branching in fetal rat lung explants and decreased the activity of p38, JNK, ERK, and STAT signaling pathways in the context of congenital diaphragmatic hernia. Ex vivo fetal lung culture, EFNB2 protein supplementation, Western blot for signaling pathways, morphometric analysis of branching International journal of molecular medicine Low 30106123
2024 TAMs expressing EFNB2 interact with gastric cancer tumor cells expressing EPHB2 via forward downstream signaling, leading to circadian rhythm disorder (CRD) in tumor cells and enhancement of the Warburg effect in metastatic liver niches. Co-culture experiments, 3D cell culture, intrasplenic injection in vivo model, clodronate macrophage depletion, bone marrow transplantation, EPH inhibitor treatment, PDX model Cellular oncology (Dordrecht, Netherlands) Medium 39298082
2024 In a preclinical HNSCC model, vascular EFNB2 knockout combined with radiation therapy enhanced anti-tumor immunity, reduced Treg accumulation, and decreased metastasis; EFNB2-Fc fusion protein targeting the EphB4-ephrinB2 axis reduced local tumor growth and distant metastasis. Vascular-specific EFNB2 knockout mouse model, radiation therapy combination, tumor microenvironment immune profiling, EFNB2-Fc and Fc-TNYL-RAW-GS peptide treatment, preclinical HNSCC models bioRxiv (preprint)preprint Low bio_10.1101_2024.07.21.604518
2025 Reactivation of the EFNB2 pathway by exogenous EFNB2 recombinant protein rescued dendritic outgrowth deficits in Zmiz1 mutant cortical neurons, placing EFNB2 as a downstream effector of the transcriptional regulator ZMIZ1 in cortical neuron development. Zmiz1 forebrain-specific conditional knockout mice, transcriptomic analysis, exogenous EFNB2 recombinant protein rescue experiment, dendritic morphology quantification bioRxiv (preprint)preprint Low bio_10.1101_2024.08.18.608498

Source papers

Stage 0 corpus · 40 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2000 Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America 86 10984508
1999 High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas. Clinical cancer research : an official journal of the American Association for Cancer Research 74 10389937
2019 Induced Expression of VEGFC, ANGPT, and EFNB2 and Their Receptors Characterizes Neovascularization in Proliferative Diabetic Retinopathy. Investigative ophthalmology & visual science 53 31574534
2011 Efnb1 and Efnb2 proteins regulate thymocyte development, peripheral T cell differentiation, and antiviral immune responses and are essential for interleukin-6 (IL-6) signaling. The Journal of biological chemistry 50 21976681
1995 Isolation of LERK-5: a ligand of the eph-related receptor tyrosine kinases. Molecular immunology 49 8559144
2016 MicroRNA-137 Inhibits EFNB2 Expression Affected by a Genetic Variant and Is Expressed Aberrantly in Peripheral Blood of Schizophrenia Patients. EBioMedicine 47 27650867
2015 Sox7 controls arterial specification in conjunction with hey2 and efnb2 function. Development (Cambridge, England) 44 25834021
2020 EFNB2 facilitates cell proliferation, migration, and invasion in pancreatic ductal adenocarcinoma via the p53/p21 pathway and EMT. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 39 32036221
2008 Dynamic changes occur in patterns of endometrial EFNB2/EPHB4 expression during the period of spiral arterial modification in mice. Biology of reproduction 34 18463357
2022 Elevated ITGA5 facilitates hyperactivated mTORC1-mediated progression of laryngeal squamous cell carcinoma via upregulation of EFNB2. Theranostics 32 36438491
2013 De novo 13q deletions in two patients with mild anorectal malformations as part of VATER/VACTERL and VATER/VACTERL-like association and analysis of EFNB2 in patients with anorectal malformations. American journal of medical genetics. Part A 32 24038947
2007 Mutational analyses of UPIIIA, SHH, EFNB2 and HNF1beta in persistent cloaca and associated kidney malformations. Journal of pediatric urology 24 17476318
2022 Adaptive activation of EFNB2/EPHB4 axis promotes post-metastatic growth of colorectal cancer liver metastases by LDLR-mediated cholesterol uptake. Oncogene 22 36376513
2018 EFNB2 haploinsufficiency causes a syndromic neurodevelopmental disorder. Clinical genetics 22 29508392
2015 Role of EFNB1 and EFNB2 in Mouse Collagen-Induced Arthritis and Human Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, N.J.) 19 25779027
2016 Reduced blood pressure after smooth muscle EFNB2 deletion and the potential association of EFNB2 mutation with human hypertension risk. European journal of human genetics : EJHG 16 27530629
2010 Is the EFNB2 locus associated with schizophrenia? Single nucleotide polymorphisms and haplotypes analysis. Psychiatry research 15 20483485
2016 NOTCH4 signaling controls EFNB2-induced endothelial progenitor cell dysfunction in preeclampsia. Reproduction (Cambridge, England) 14 27069008
2020 Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions. Scientific reports 12 31949258
2012 T cell-specific deletion of EFNB2 minimally affects T cell development and function. Molecular immunology 12 22673212
2003 Increased messenger RNA for allograft inflammatory factor-1, LERK-5, and a novel gene in 17.5-day relative to 15.5-day bovine embryos. Biology of reproduction 12 12773430
2022 Tracheal separation is driven by NKX2-1-mediated repression of Efnb2 and regulation of endodermal cell sorting. Cell reports 11 35294885
2021 Efnb2 haploinsufficiency induces early gap junction plaque disassembly and endocytosis in the cochlea. Brain research bulletin 9 34139316
2018 Upregulated EFNB2 and EPHB4 promotes lung development in a nitrofen-induced congenital diaphragmatic hernia rat model. International journal of molecular medicine 9 30106123
2015 Role of EFNB2/EPHB4 signaling in spiral artery development during pregnancy: An appraisal. Molecular reproduction and development 9 26501487
2015 Identification of CCL2, RARRES2 and EFNB2 as host cell factors that influence the multistep replication of respiratory syncytial virus. Virus research 7 26277777
2024 Ephrin B2 (EFNB2) potentially protects against intervertebral disc degeneration through inhibiting nucleus pulposus cell apoptosis. Archives of biochemistry and biophysics 5 38636690
2023 Theranostic Potential of EFNB2 for Cetuximab Resistance in Head and Neck Cancer. Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India 5 37636764
2024 Inducible deletion of endothelial cell Efnb2 delays capillary regeneration and attenuates myofibre reinnervation following myotoxin injury in mice. The Journal of physiology 4 39196901
2024 Circadian system disorder induced by aberrantly activated EFNB2-EPHB2 axis leads to facilitated liver metastasis in gastric cancer. Cellular oncology (Dordrecht, Netherlands) 4 39298082
2021 miR-193a-3p Mediates Placenta Accreta Spectrum Development by Targeting EFNB2 via Epithelial-Mesenchymal Transition Pathway Under Decidua Defect Conditions. Frontiers in molecular biosciences 4 33585562
2011 Generation of transgenic mice overexpressing EfnB2 in endothelial cells. Genesis (New York, N.Y. : 2000) 3 21735541
2023 The Therapeutic Effects of EFNB2-Fc in a Cell Model of Kawasaki Disease. Pharmaceuticals (Basel, Switzerland) 2 37111257
2025 Exploring the causal relationship between serum EFNB2 levels and epilepsy: a bidirectional Mendelian randomization and co-localization analysis. BMC neurology 1 40045230
2026 Mild hypothermia inhibits the inflammatory response and microglial M1 polarization in ischemic stroke via the EFNB2/EphB4 pathway. Metabolic brain disease 0 42159828
2025 A long non-coding RNA Leat1 mediates the hormone responsiveness of EfnB2 during male urogenital development. Communications biology 0 41398470
2024 LncRNA BBOX1-AS1 Contributes to Laryngeal Carcinoma Progression by Recruiting SRSF1 to Maintain EFNB2 mRNA Stability. Biochemical genetics 0 38965134
2023 A long non-coding RNA Leat1 mediates the hormone responsiveness of EfnB2 during male urogenital development. Research square 0 37461443
2022 Corrigendum: miR-193a-3p Mediates Placenta Accreta Spectrum Development by Targeting EFNB2 via Epithelial-Mesenchymal Transition Pathway Under Decidua Defect Conditions. Frontiers in molecular biosciences 0 35242814
2021 Generation of an EFNB2-2A-mCherry reporter human embryonic stem cell line using CRISPR/Cas9-mediated site-specific homologous recombination. Stem cell research 0 33611045

Missed literature

Know a paper Affinage missed for EFNB2? Flag it for the maintainers and the community.

No submissions yet.